Neuroimaging Biomarkers in Schizophrenia.

Neuroimaging Biomarkers in Schizophrenia.
复制标题

精神分裂症的神经影像学生物标志物。

DOI:
10.1176/appi.ajp.2020.20030340
复制
发表时间:
2021-06
期刊:
The American journal of psychiatry
影响因子:
--
通讯作者:
Nemeroff CB
Nemeroff CB
中科院分区:
其他
文献类型:
--
作者:
Kraguljac NV;McDonald WM;Widge AS;Rodriguez CI;Tohen M;Nemeroff CB

文献摘要

参考文献

被引文献

相似文献

精神分裂症是一种复杂的神经精神综合征,具有异质性的遗传,神经生物学和表型。目前,没有客观的生物测量,即生物标志物,可用于告知诊断或治疗决策。神经影像学在精神分裂症的生物标志物开发中处于有利地位,因为它可以捕获分子和细胞疾病靶点或脑回路中的表型变异。这些基于机制的生物标志物可以代表疾病过程的病理生理学基础的直接测量,因此可以作为真正的中间或替代终点。有效的生物标志物可以验证新的治疗靶点或途径,预测反应,帮助选择患者进行治疗,确定治疗方案,并为个性化治疗提供依据。在这篇综述中,我们讨论了一系列机制上合理的神经影像学生物标志物候选者,包括多巴胺功能亢进,N-甲基-d-天冬氨酸受体功能减退,海马功能亢进,免疫失调,连接障碍,和皮质灰质体积损失。然后,我们专注于精神分裂症的疾病风险,诊断,目标参与和治疗反应的假定神经影像学生物标志物。最后,我们强调了未满足的需求领域,并讨论了推进生物标志物开发的策略。
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological and phenotypic profile. Presently, no objective biological measures, i.e. biomarkers, are available to inform diagnostic or treatment decisions. Neuroimaging is well positioned for biomarker development in schizophrenia, as it may capture phenotypic variations in molecular and cellular disease targets, or in brain circuits. These mechanistically based biomarkers may represent a direct measure of the pathophysiological underpinnings of the disease process, and thus could serve as true intermediate or surrogate endpoints. Effective biomarkers could validate new treatment targets or pathways, predict response, aid in selection of patients for therapy, determine regimens, and provide rationale for personalized treatments. In this review, we discuss a range of mechanistically plausible neuroimaging biomarker candidates, including dopamine hyperactivity, N-methyl-d-aspartate receptor hypofunction, hippocampal hyperactivity, immune dysregulation, dysconnectivity, and cortical gray matter volume loss. We then focus on the putative neuroimaging biomarkers for disease risk, diagnosis, target engagement and treatment response in schizophrenia. Finally, we highlight areas of unmet needs and discuss strategies to advance biomarker development.
DOI: 10.1186/s13550-018-0424-2
发表时间: 2018-07-27
期刊: EJNMMI research
影响因子: 3.2
作者:
van der Aart J;Golla SSV;van der Pluijm M;Schwarte LA;Schuit RC;Klein PJ;Metaxas A;Windhorst AD;Boellaard R;Lammertsma AA;van Berckel BNM
通讯作者: van Berckel BNM
DOI: 10.1093/schbul/sbs076
发表时间: 2012-09-01
影响因子: 6.6
作者:
Coyle, Joseph T.
通讯作者: Coyle, Joseph T.
DOI: 10.3371/csrp.4.4.2
发表时间: 2011-01-01
影响因子: --
作者:
Bodnar, Michael;Harvey, Philippe-Olivier;Lepage, Martin
通讯作者: Lepage, Martin
DOI: 10.1016/s1474-4422(08)70224-2
发表时间: 2008-12
期刊: LANCET NEUROLOGY
影响因子: 48
作者:
Dalmau, Josep;Gleichman, Amy J.;Hughes, Ethen G.;Rossi, Jeffrey E.;Peng, Xiaoyu;Lai, Meizan;Dessain, Scott K.;Rosenfeld, Mynna R.;Balice-Gordon, Rita;Lynch, David R.
通讯作者: Lynch, David R.
DOI: 10.1073/pnas.97.14.8104
发表时间: 2000-07-05
影响因子: 11.1
作者:
Abi-Dargham, A;Rodenhiser, J;Laruelle, M
通讯作者: Laruelle, M